
(in millions)	Cardiovascular		Neuroscience		Medical Surgical		Diabetes		Total
April 28, 2023	$	7,873	$	11,718	$	19,579	$	2,255	$	41,425
Goodwill as a result of acquisitions	131		—		—		—		131
Purchase accounting adjustments	(5)		—		—		—		(5)
Currency translation and other	(33)		(74)		(458)		—		(565)
April 26, 2024	7,966		11,644		19,121		2,255		40,986
Goodwill as a result of acquisitions	—		—		108		—		108
Purchase accounting adjustments	2		—		(2)		—		—
Currency translation and other	50		72		521		1		643
April 25, 2025	$	8,017	$	11,716	$	19,748	$	2,255	$	41,737

The Company did not recognize any goodwill impairment charges during fiscal years 2025 or 2024. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $208 million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61 million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in other operating (income) expense, net in the consolidated statements of income.


	April 25, 2025				April 26, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,550	$	(9,650)	$	16,518	$	(8,689)
Purchased technology and patents	11,600		(7,514)		11,557		(6,868)
Trademarks and tradenames	421		(283)		424		(274)
Other	355		(101)		256		(84)
Total	$	28,925	$	(17,547)	$	28,755	$	(15,915)
Indefinite-lived:
IPR&D	$	289	$	—	$	385	$	—

The Company did not recognize any definite-lived intangible asset impairment charges during fiscal years 2025 and 2023. During fiscal year 2024, the Company recognized $295 million of definite-lived intangible asset impairment charges in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. The intangible asset impairment charges are recognized in other operating (income) expense, net in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024.

There were no indefinite-lived intangible asset impairment charges during fiscal year 2025. Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2024 and 2023. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Intangible asset amortization expense was $1.8 billion for fiscal year 2025, including $151 million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. Intangible asset amortization expense was $1.7 billion for fiscal years 2024 and 2023. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April 25, 2025, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows: